Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

Aya Shiba‐Ishii, Ted W. Johnson, Ibiayi Dagogo‐Jack, Mari Mino–Kenudson, Theodore R. Johnson, Ping Wei, Scott L. Weinrich, Michele McTigue, Makeba Walcott, Linh Nguyen-Phuong, Kristin Dionne, Adam Acker, Lesli A. Kiedrowski, Andrew Do, Jennifer Peterson, Jaimie L. Barth, Beow Y. Yeap, Justin F. Gainor, Jessica J. Lin, Satoshi Yoda, Aaron N. Hata